Johnson & Johnson Vision’s TearScience, LipiScan® and LipiFlow® are now available to image meibomian glands and treat meimbomian gland dysfunction.
Meibomian gland dysfunction (MGD) is a primary cause of dry eye disease, which impacts more than 340 million people globally.
It is an incredible opportunity to help patients and achieve practice growth.
MGD is a leading cause of dry eye, found in an estimated 86% of dry eye patients. The LipiFlow® System is a best-in-class medical device treatment for MGD shown to improve mean gland function and dry eye symptoms. The efficacy of LipiFlow® is supported by 30 peer-reviewed reports. LipiScan® is the first and only dedicated rapid high definition gland imager.
Most optical sales incentive programs involve either set production benchmarks or the achievement of target percentages of total items or services sold.
Production benchmarks generally account for unexpectedly low volume days, while target percentages usually include a minimum production safeguard to ensure bonuses are paid only after the office reaches a certain profit level.
For example, an operator may see an opportunity in AR sales and offers the staff $50 whenever at least 10 coatings are sold. Another practitioner may simply offer a bonus whenever 50% of the total spectacle sales includes an AR coating. Either program illustrates an effective benchmarking system.
Business Building Idea of the Week
Senior centers, assisted living facilities, and retirement homes are places where you can speak and provide practical health information on cataracts, glaucoma, and other common age-related eye complications that senior patients experience.
Creating an outreach program with the senior audience will again get you further involved with your local community, and help create brand awareness for an audience who isn’t online or as tech-savvy as most other generations.
SNAPP Thought of the Week
“When the winds of change blow, some build walls and others build windmills.”